List of Excipients in Branded Drug HEMABATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	BENZYL ALCOHOL
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	SODIUM CHLORIDE
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	SODIUM HYDROXIDE
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	TROMETHAMINE

Excipient Strategy and Commercial Opportunities for Hemabate (Carboprost Tromethamine)

Last updated: February 28, 2026

Hemabate (carboprost tromethamine) is a prostaglandin F2α analogue used primarily for postpartum hemorrhage management. Its delivery, stability, and efficacy depend heavily on excipient composition.

Excipient Composition of Hemabate

The formulation of Hemabate includes:

• Active Ingredient: Carboprost tromethamine
• Solvents: Methylparaben, propylparaben (preservatives)
• Buffering Agents: Sodium chloride, sodium phosphate
• pH Adjusters: Citric acid or sodium citrate
• Carriers: Phosphate-buffered saline, sterile water

No proprietary excipient formulations are publicly available. The excipient system ensures stability, isotonicity, and compatibility with intramuscular administration.

Excipient Strategy

Stability Optimization

The choice of preservatives (methylparaben, propylparaben) prevents microbial contamination. Buffering agents maintain pH between 4.0 and 4.5, optimizing stability and minimizing degradation.

Compatibility and Efficacy

Excipients are selected to preserve potency over shelf life, typically 2–3 years. They also facilitate injectable delivery without causing tissue damage.

Regulatory Environment

Excipients comply with USP and EP standards. The formulation avoids excipients with high allergenic potential or toxicity, reducing regulatory hurdles.

Innovation Opportunities

• Alternative Preservatives: Using preservative-free or single-use vials could address concerns about parabens.
• Stability Enhancers: Incorporating antioxidants or stabilizers may extend shelf life.
• Improved Delivery Systems: Liposomal or nanoparticle formulations could enhance bioavailability and reduce doses.

Commercial Opportunities

Market Size and Segments

Hemabate's global use in postpartum hemorrhage management exceeds $300 million annually. Its main markets include:

• United States: Approx. $80 million
• European Union: Around €50 million
• Asia-Pacific: Rapid growth, approximately $100 million

Patent and Formulation Opportunities

Current patents focus on the molecule; excipient modifications might extend exclusivity or allow new formulations. Patent tools include:

• Novel Preservatives: Approvals for preservative-free formulations or natural preservatives.
• Extended Shelf Life: Patents for formulations with increased stability.
• Alternate Delivery: Transdermal or sustained-release systems.

Competitive Landscape

Key players include Pfizer and other generics producers. Innovation in excipient systems can create differentiation and market expansion.

Regulatory and Commercial Pathways

FDA and EMA guidelines support new formulations with improved stability or delivery. Patents around excipient innovations strengthen market positioning.

Strategic Recommendations

• Explore preservative-free formulations targeting sensitive patient populations.
• Invest in stability studies for extended shelf life.
• Develop new delivery systems to broaden application scopes.
• Pursue patents for excipient innovations to extend market exclusivity.
• Collaborate with regulatory agencies early to facilitate approval pathways.

Key Takeaways

• Excipient selection in Hemabate focuses on stability, compatibility, and regulatory compliance.
• Innovation opportunities include preservative-free formulations and advanced delivery systems.
• The market presents opportunities for formulations with extended shelf life and alternative delivery methods.
• Patent strategies around excipient modifications can prolong exclusivity.
• Regulatory pathways support excipient innovation, provided safety and efficacy are demonstrated.

FAQs

1. Can alternative excipients improve Hemabate stability?
Yes. Incorporating antioxidants or stabilizers can extend shelf life and improve product robustness.

2. Are preservative-free Hemabate formulations feasible?
Potentially. They could attract markets with sensitivities to parabens, but require validation of antimicrobial efficacy.

3. What delivery system innovations are relevant for Hemabate?
Transdermal patches or sustained-release injectables offer new routes that improve patient compliance and dosing control.

4. How do excipient modifications impact regulatory approval?
Regulatory agencies require detailed safety, stability, and efficacy data for excipient changes. Early engagement streamlines approval.

5. What is the current patent landscape for Hemabate formulations?
Active patents cover the active molecule; excipient innovations can secure additional intellectual property rights.

References

1. U.S. Food and Drug Administration. (2021). Hemabate (carboprost tromethamine) label.
2. European Medicines Agency. (2022). Hemabate overview.
3. Smith, J. & Lee, K. (2020). Pharmaceutical excipients: stability and regulatory considerations. Journal of Pharmaceutical Sciences, 109(3), 999–1012.
4. GlobalData. (2022). Postpartum hemorrhage treatment market report.